文献
J-GLOBAL ID:202002285538476640
整理番号:20A2190980
白金耐性卵巣癌におけるペンブロリズマブとペグ化リポソームドキソルビシンの併用:第2相臨床試験【JST・京大機械翻訳】
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
著者 (25件):
Lee Elizabeth K.
(Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Xiong Niya
(Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Cheng Su-Chun
(Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Barry William T.
(Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Penson Richard T.
(Department of Medical Gynecologic Oncology, Massachusetts General Hospital, Boston, MA, United States of America)
,
Konstantinopoulos Panagiotis A.
(Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Konstantinopoulos Panagiotis A.
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Hoffman Mark A.
(Long Island Jewish Medical Center, New Hyde Park, NY, United States of America)
,
Horowitz Neil
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Horowitz Neil
(Department of Obstetrics & Gynecology, Brigham & Women’s Hospital, Boston, MA, United States of America)
,
Dizon Don S.
(Brown University, Division of Women’s Cancers, Lifespan Cancer Institute, Providence, RI, United States of America)
,
Stover Elizabeth H.
(Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Stover Elizabeth H.
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Wright Alexi A.
(Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Wright Alexi A.
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Campos Susana M.
(Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Campos Susana M.
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Krasner Carolyn
(Department of Medical Gynecologic Oncology, Massachusetts General Hospital, Boston, MA, United States of America)
,
Morrissey Stephanie
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Whalen Christin
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Quinn Roxanne
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Matulonis Ursula A.
(Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Matulonis Ursula A.
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Liu Joyce F.
(Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
,
Liu Joyce F.
(Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America)
資料名:
Gynecologic Oncology
(Gynecologic Oncology)
巻:
159
号:
1
ページ:
72-78
発行年:
2020年
JST資料番号:
E0561C
ISSN:
0090-8258
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)